Inventor · disambiguated record
Cecile Chartier-Courtaud
Also filed as: CHARTIER-COURTAUD CECILE · CHARTIER-COURTAUD CÉCILE
12 granted patents·23 pending applications·61 citations·filing 2011–2025
90Inventor score
Files withIOVANCE BIOTHERAPEUTICS INC25ONCOMED PHARM INC6CHARTIER-COURTAUD CECILE1GURNEY AUSTIN L1NEXTVIVO INC1
Top patents by PatentIndex Score
35 records- 0196US11713446B2Processes for generating TIL products enriched for tumor antigen-specific T-cellsIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Aug 1, 2023·18 cites·26 claims
- 0296US11384337B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Granted Jul 12, 2022·7 cites·28 claims
- 0394US12031157B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Jul 9, 2024·2 cites·30 claims
- 0494US12024718B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Jul 2, 2024·2 cites·30 claims
- 0594US8802097B2Anti-RSPO1 antibodiesGURNEY AUSTIN L·Filed 2012·Granted Aug 12, 2014·12 cites·15 claims
- 0693US12495791B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Dec 16, 2025·1 cites·30 claims
- 0793US9109025B2Anti-RSPO2 antibodiesONCOMED PHARM INC·Filed 2014·Granted Aug 18, 2015·9 cites·19 claims
- 0890US9109024B2Anti-RSPO1 antibodies and uses thereofONCOMED PHARM INC·Filed 2014·Granted Aug 18, 2015·5 cites·21 claims
- 0987US12104172B2Processes for generating TIL products enriched for tumor antigen-specific t-cellsIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Granted Oct 1, 2024·3 cites·13 claims
- 1086US12343380B2Expansion of TILs utilizing AKT pathways inhibitorsIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Granted Jul 1, 2025·2 cites·28 claims
- 1181US11866688B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 9, 2024·0 cites·9 claims
- 1281US2024398946A1Til expansion from fine needle aspirates and small biopsiesIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1376US2024390424A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1476US2024408136A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1575US2025066730A1Processes for generating til products enriched for tumor antigen-specific t-cellsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1673US2021130779A1Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1770US2021309968A1Til expansion from fine needle aspirates and small biopsiesIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1868US2020277573A1Til expansion from fine needle aspirates and small biopsiesIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1967US2024307437A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2067US2025188413A1Til expansion from fine needle aspirates and small biopsiesIOVANCE BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2163US9644034B2Anti-RSPO2 antibodies and uses thereofONCOMED PHARM INC·Filed 2015·Granted May 9, 2017·0 cites·21 claims
- 2263US2017298143A1Rspo binding agents and uses thereofONCOMED PHARM INC·Filed 2017·Application pending·0 cites
- 2360US2025099588A1Cytokine associated tumor infiltrating lymphocytes compositions and methodsIOVANCE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2456US2024299540A1Adjuvant therapy for cancerIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2555US2022389381A1Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2655US2022193131A1Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses ThereofIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2753US2025169802A1Systems and methods of enhancing tumor-reactive immune populations with organoidsNEXTVIVO INC·Filed 2024·Application pending·0 cites
- 2852US2024191191A1Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tilsIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2950US2022112557A1System and methods for monitoring adoptive cell therapy clonality and persistenceIOVANCE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3050US2014056890A1Binding Agents That Modulate the Hippo Pathway and Uses ThereofONCOMED PHARM INC·Filed 2013·Application pending·0 cites
- 3148US2022249559A1Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3247US2018118825A1Binding Agents That Modulate the Hippo Pathway and Uses ThereofONCEMED PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3347US2023039976A1Selection of improved tumor reactive t-cellsIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3441US2019048094A1Redirecting immune responsesONCOMED PHARM INC·Filed 2017·Application pending·0 cites
- 3540US2013089560A1Bone morphogenetic protein receptor binding agents and methods of their useCHARTIER-COURTAUD CECILE·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cecile Chartier-Courtaud files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →